3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Breast
1
Conditions
Sarcoma
3
Neoplasm Metastasis
3
Colorectal Neoplasms
3
Sarcoma, Ewing
2
Ovarian Neoplasms
2
Carcinoid Tumor
2
Breast Neoplasms
2
Adenocarcinoma
2
Triple Negative Breast Neoplasms
1
Recurrence
1
Rectal Neoplasms
1
Pathologic Complete Response
1
Pancreatic Neoplasms
1
Neuroendocrine Tumors
1
Neuroectodermal Tumors, Primitive
1
Neoplasms
1
Lymphoma
1
Insulin-Like Growth Factor I, Resistance To
1
Hemangiosarcoma
1
Colonic Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Askin Tumor
1
Adenoma, Islet Cell
1
Interventions
Paclitaxel
6
Doxorubicin
6
Gemcitabine
4
Bevacizumab
4
pembrolizumab
3
pazopanib
3
durvalumab
3
Sorafenib
3
Docetaxel
3
trebananib
2
spartalizumab
2
cemiplimab
2
brostallicin
2
Propranolol
2
Nivolumab
2
Magnetic Resonance Spectroscopy
2
Ipilimumab
2
Imatinib Mesylate
2
Ifosfamide
2
Carboplatin
2
3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione
2
zanidatamab
1
veliparib
1
tucatinib
1
trilaciclib
1
tremelimumab
1
trastuzumab duocarmazine
1
temsirolimus
1
talimogene laherparepvec
1
talazoparib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Hemangiosarcoma
×
ganitumab
×
Clear all
NCT01042379
2026-05-06
I-SPY
QuantumLeap Healthcare Collaborative
Phase 2
Recruiting
5,000 enrolled